Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug interactions with fluoroquinolones.

G E Stein1

  • 1Department of Medicine, Michigan State University, East Lansing 48824.

The American Journal of Medicine
|December 30, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-anaerobic activity of serum from patients treated with tigecycline for skin/soft tissue infections.

Anaerobe·2011
Same author

Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp.

The Journal of antimicrobial chemotherapy·2009
Same author

Symmetry breaking of in-plane order in confined copolymer mesophases.

Physical review letters·2007
Same author

Single-crystal diffraction from two-dimensional block copolymer arrays.

Physical review letters·2007
Same author

Standardization of broth microdilution and disk diffusion susceptibility tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: quality control standards for ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole.

Journal of clinical microbiology·2001
Same author

Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae.

Diagnostic microbiology and infectious disease·2001

Fluoroquinolone antibiotics can interact with other drugs, affecting absorption and metabolism. These interactions, particularly with metal cations and methylxanthines, are manageable through dose adjustments and careful drug selection.

Area of Science:

  • Pharmacology
  • Microbiology
  • Drug Interactions

Background:

  • Fluoroquinolones are a significant class of antimicrobial agents used for bacterial infections.
  • Their complex pharmacokinetic profiles present a risk for various drug interactions.
  • Understanding these interactions is crucial for safe and effective patient care.

Purpose of the Study:

  • To review and summarize the known drug interactions associated with fluoroquinolone antibiotics.
  • To highlight the clinical significance and management strategies for identified interactions.
  • To emphasize the need for ongoing surveillance as fluoroquinolone use increases.

Main Methods:

  • Literature review of well-studied fluoroquinolone drug interactions.
  • Analysis of pharmacokinetic data related to absorption and metabolism.

Related Experiment Videos

  • Discussion of reported but less-studied interactions.

    • Main Results:

    • Two primary interactions are well-documented: decreased fluoroquinolone absorption with multivalent metal cations and inhibited methylxanthine metabolism by certain fluoroquinolones (e.g., ciprofloxacin, enoxacin, norfloxacin).
    • Management strategies include dose staggering for metal cation interactions and using newer fluoroquinolones or monitoring theophylline levels for methylxanthine interactions.
    • Other potential interactions with cyclosporine, warfarin, and NSAIDs require further investigation.

    Conclusions:

    • Fluoroquinolone drug interactions, particularly with metal cations and methylxanthines, are clinically significant but manageable.
    • Appropriate dosing strategies and selection of newer agents can mitigate risks.
    • Continued vigilance and patient monitoring are essential to identify and prevent future fluoroquinolone-related drug interactions.